Close Menu

NEW YORK (GenomeWeb) – Luminex announced today it has licensed the Xtreme Chain Reaction nucleic acid amplification technology from XCR Diagnostics.

The XCR technology enables rapid thermal cycling protocols in order to reduce assay turnaround times compared to traditional PCR.

"We look forward to leveraging the benefits that the XCR technology can bring to our future molecular diagnostics portfolio," Luminex President and CEO Homi Shamir said in a statement.

Financial terms for the non-exclusive, worldwide licensing agreement were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.

Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.

Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.

In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.

Jun
11
Sponsored by
Roche

This webinar will overview the potential for liquid biopsy approaches to monitor therapy resistance in lung cancer.

Jun
18
Sponsored by
ArcherDX

This webinar will discuss background and clinical genomics of NTRK fusion detection in cancer. NTRK fusions are the focus of new therapeutic options, but clonal and subclonal lesions are notoriously difficult to detect. 

Jul
24
Sponsored by
Hologic

This webinar will share the results of comparisons of commercially available nucleic acid amplification tests for use in routine screening of pregnant women for Group B Streptococcus (GBS).